Free shipping on all orders over $ 500

Tebentafusp

Cat. No. M24837

All AbMole products are for research use only, cannot be used for human consumption.

Tebentafusp Structure
Synonym:

IMCgp100

Price and Availability

For this product's availability, delivery time and price, please email [email protected] directly or click the "Inquiry Now" button below.


Quality Control & Documentation
Biological Activity

Tebentafusp (IMCgp100) is a bispecific fusion protein to target gp100 peptide-HLA-A*02:01 (a melanoma-associated antigen). Tebentafusp guides T cells to kill gp100-expressing tumor cells via a high affinity T-cell receptor (TCR) binding domain and an anti-CD3 T-cell engaging domain. Tebentafusp leads to inflammatory cytokines and cytolytic proteins production, resulting in the direct lysis of tumour cells.

Chemical Information
CAS Number 1874157-95-5
Storage Please store the product under the recommended conditions in the Certificate of Analysis.
References

[1] Sohita Dhillon. Drugs. Tebentafusp: First Approval

[2] Timo E Schank, et al. Future Oncol. Tebentafusp for the treatment of metastatic uveal melanoma

[3] Paul Nathan, et al. N Engl J Med. Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma

[4] Mark R Middleton, et al. Clin Cancer Res. Tebentafusp, A TCR/Anti-CD3 Bispecific Fusion Protein Targeting gp100, Potently Activated Antitumor Immune Responses in Patients with Metastatic Melanoma

[5] Bertil E Damato, et al. Cancers (Basel). Tebentafusp: T Cell Redirection for the Treatment of Metastatic Uveal Melanoma

Related Fusion Proteins Products
Conbercept

Conbercept (KH902) is a monoclonal antibody targeting VEGFRA fused to the IGHG1 Fc fragment. Conbercept is produced by the fusion of the second C-LIKE of FLT1 and the third and fourth C-LIKE of KDR with IGHG1 Fc.

Evorpacept

Evorpacept (ALX148) is a high affinity CD47-blocking fusion protein with an inactive human immunoglobulin Fc region designed to enhance the activity of other anti-neoplastic therapies, with minimal additional toxicity.

Belatacept

Belatacept (BMS 224818) is a fusion protein composed of the Fc fragment of a human IgG1 immunoglobulin linked to the extracellular domain of CTLA-4, which is a molecule crucial in the regulation of T cell costimulation, selectively blocking the process of T-cell activation. Belatacept binds to CD 80/86 ligands and thereby inhibits the CD-28-mediated T-cell costimulation. Belatacept can be used in the research of Immunosuppression in organ transplants.

Baminercept

Baminercept (BG 9924) is a lymphotoxin β receptor IgG fusion protein (LTβR-Ig). Baminercept can be used for the research of many autoimmune diseases including primary Sjögren's syndrome (SS) and rheumatoid arthritis (RA) .

Briobacept

Briobacept (BR 3FC) is a selective human monoclonal antibody targeting to BLyS (BAFF), induces B cells apoptosis. Briobacept is a recombinant glucoprotein, consists of 2 molecules from the BLyS receptor (BR3)and a Fc domain of human IgG1. Briobacept can be used in studies of rheumatoid arthritis (RA).

  Catalog
Abmole Inhibitor Catalog




Keywords: Tebentafusp, IMCgp100 supplier, Fusion Proteins, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.